Plasma exchange in Kawasaki disease.

Suppr

超能文献

作者信息

Takagi N, Kihara M, Yamaguchi S, Tamura K, Yabana M, Tokita Y, Ishii M

出版信息

Lancet. 1995 Nov 11;346(8985):1307. doi: 10.1016/s0140-6736(95)91916-3.

DOI:10.1016/s0140-6736(95)91916-3

PMID:7475760

Abstract

摘要

相似文献

Plasma exchange in Kawasaki disease.

Lancet. 1995 Nov 11;346(8985):1307. doi: 10.1016/s0140-6736(95)91916-3.

Rupture of coronary aneurysm in Kawasaki disease.

Pediatr Int. 1999 Jun;41(3):318-20. doi: 10.1046/j.1442-200x.1999.01058.x.

Rapidly progressive dilatation of coronary artery aneurysm associated with Kawasaki disease.

Eur J Pediatr. 2007 Jan;166(1):87; author reply 89-90; discussion 91. doi: 10.1007/s00431-006-0199-8. Epub 2006 Jul 22.

Kawasaki disease.

Rheum Dis Clin North Am. 2015;41(1):63-73, viii. doi: 10.1016/j.rdc.2014.09.010.

The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.

J Pediatr. 2017 Dec;191:140-144. doi: 10.1016/j.jpeds.2017.08.076.

Kawasaki disease.

Pediatr Emerg Care. 2003 Dec;19(6):422-4. doi: 10.1097/01.pec.0000101587.65509.90.

[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm].

Zhonghua Er Ke Za Zhi. 2009 May;47(5):384-5.

Vasculitis, Kawasaki disease, and hemolytic uremic syndrome.

Curr Opin Rheumatol. 1994 Sep;6(5):530-6. doi: 10.1097/00002281-199409000-00013.

[Kawasaki disease; what to look for and what to do?].

Ned Tijdschr Geneeskd. 1995 Mar 18;139(11):545-7.

Epidemiology, etiology, and management of Kawasaki disease: state of the art.

Pediatr Cardiol. 1999 May-Jun;20(3):177-83. doi: 10.1007/s002469900436.

引用本文的文献

Plasmapheresis for systemic vasculitis.

Ther Apher Dial. 2022 Jun;26(3):493-506. doi: 10.1111/1744-9987.13829. Epub 2022 Mar 16.

The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease.

J Clin Med. 2021 Mar 4;10(5):1062. doi: 10.3390/jcm10051062.

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.

Curr Opin Pharmacol. 2020 Oct;54:72-81. doi: 10.1016/j.coph.2020.08.008. Epub 2020 Sep 18.

Kawasaki disease.

Yonsei Med J. 2006 Dec 31;47(6):759-72. doi: 10.3349/ymj.2006.47.6.759.

Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease.

J Clin Immunol. 2005 Jul;25(4):309-13. doi: 10.1007/s10875-005-4697-7.

Current perspectives on Kawasaki disease.

Indian J Pediatr. 2005 Jul;72(7):621-9. doi: 10.1007/BF02724189.

Advances in Kawasaki disease.

Eur J Pediatr. 2004 Jun;163(6):285-91. doi: 10.1007/s00431-004-1431-z.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Plasma exchange in Kawasaki disease.

Lancet. 1995 Nov 11;346(8985):1307. doi: 10.1016/s0140-6736(95)91916-3.

Rupture of coronary aneurysm in Kawasaki disease.

Pediatr Int. 1999 Jun;41(3):318-20. doi: 10.1046/j.1442-200x.1999.01058.x.

Rapidly progressive dilatation of coronary artery aneurysm associated with Kawasaki disease.

Eur J Pediatr. 2007 Jan;166(1):87; author reply 89-90; discussion 91. doi: 10.1007/s00431-006-0199-8. Epub 2006 Jul 22.

Kawasaki disease.

Rheum Dis Clin North Am. 2015;41(1):63-73, viii. doi: 10.1016/j.rdc.2014.09.010.

The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.

J Pediatr. 2017 Dec;191:140-144. doi: 10.1016/j.jpeds.2017.08.076.

Kawasaki disease.

Pediatr Emerg Care. 2003 Dec;19(6):422-4. doi: 10.1097/01.pec.0000101587.65509.90.

[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm].

Zhonghua Er Ke Za Zhi. 2009 May;47(5):384-5.

Vasculitis, Kawasaki disease, and hemolytic uremic syndrome.

Curr Opin Rheumatol. 1994 Sep;6(5):530-6. doi: 10.1097/00002281-199409000-00013.

[Kawasaki disease; what to look for and what to do?].

Ned Tijdschr Geneeskd. 1995 Mar 18;139(11):545-7.

Epidemiology, etiology, and management of Kawasaki disease: state of the art.

Pediatr Cardiol. 1999 May-Jun;20(3):177-83. doi: 10.1007/s002469900436.

引用本文的文献

Plasmapheresis for systemic vasculitis.

Ther Apher Dial. 2022 Jun;26(3):493-506. doi: 10.1111/1744-9987.13829. Epub 2022 Mar 16.

The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease.

J Clin Med. 2021 Mar 4;10(5):1062. doi: 10.3390/jcm10051062.

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.

Curr Opin Pharmacol. 2020 Oct;54:72-81. doi: 10.1016/j.coph.2020.08.008. Epub 2020 Sep 18.

Kawasaki disease.

Yonsei Med J. 2006 Dec 31;47(6):759-72. doi: 10.3349/ymj.2006.47.6.759.

Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease.

J Clin Immunol. 2005 Jul;25(4):309-13. doi: 10.1007/s10875-005-4697-7.

Current perspectives on Kawasaki disease.

Indian J Pediatr. 2005 Jul;72(7):621-9. doi: 10.1007/BF02724189.

Advances in Kawasaki disease.

Eur J Pediatr. 2004 Jun;163(6):285-91. doi: 10.1007/s00431-004-1431-z.